China approves Brii Biosciences' COVID-19 treatment

The medicine, a combination of BRII-196/BRII-198, was approved to treat mild COVID-19 and the disease of "normal type"

  
Zhang Tingzhen looks out of the window while sitting beside a doll given by his mother to play with at a Shenzhen hospital in southern China September 26, 2012.

Zhang Tingzhen looks out of the window while sitting beside a doll given by his mother to play with at a Shenzhen hospital in southern China September 26, 2012.

Reuters/Stringer China

BEIJING- China's medical products regulator said on Wednesday it has approved the use of BRII Biosciences'  neutrialising antibody cocktail for COVID-19, the first treatment of its type against the disease approved in the country.

The medicine, a combination of BRII-196/BRII-198, was approved to treat mild COVID-19 and the disease of "normal type" with high risk of progressing to hospitalization or death in adults and teenagers aged 12-17, the National Medical Products Administration said in a statement.

(Reporting by Roxanne Liu and Ryan Woo; Editing by Jan Harvey) ((meg.shen@thomsonreuters.com; 852-39525805;))


More From Health